The report provides a detailed analysis essential for establishing a metipranolol production plant. It encompasses all critical aspects necessary for metipranolol production, including the cost of metipranolol production, metipranolol plant cost, metipranolol production costs, and the overall metipranolol production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a metipranolol production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.
Metipranolol is a non-selective beta-adrenergic antagonist (beta-blocker) that is used as an ophthalmic solution. It is used to treat elevated intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma. It lowers IOP by reducing aqueous humour production with minimal impact on pupil size or accommodation. It helps prevent glaucomatous visual field loss and optic nerve damage when applied topically to the eye. It exhibits antiarrhythmic, antihypertensive, and antiglaucoma properties due to beta1- and beta2-receptor blockade. It is FDA-approved for glaucoma management and administered as a 0.3% solution twice daily. Its common side effects include ocular irritation (burning, stinging, itching), tearing, photophobia, blurred vision, bradycardia, fatigue, headache, and dizziness.
The market for metipranolol is driven by the need for a non-selective beta-blocker ophthalmic for glaucoma and ocular hypertension. The rising disease prevalence from ageing populations, lifestyle factors like diabetes and hypertension, and heightened awareness of early screening contribute to its market growth.
The expanding access to eye care, preference for topical beta-blockers due to efficacy in reducing intraocular pressure with fewer systemic effects than oral alternatives, boosts its market. The industrial metipranolol procurement is influenced by the presence of limited manufacturers, supply chain vulnerabilities for APIs, and regulatory hurdles for ophthalmic sterile production. Also, low profitability leading to discontinuation risks, hospital and pharmacy tender dependencies, and competition from prostaglandin analogues affect its sourcing.
Raw Material for Metipranolol Production
According to the metipranolol production plant project report, the key raw materials used in the production of metipranolol include 4-O-acetyl-2,3,5-trimethylhydroquinone and (R)- or (S)-epichlorohydrin.
Production Process of Metipranolol
The extensive metipranolol production cost report consists of the following major industrial production process:
- From 4-O-acetyl-2,3,5-trimethylhydroquinone: The production process of metipranolol involves several steps. It starts with a reaction of 4-O-acetyl-2,3,5-trimethylhydroquinone with (R)- or (S)-epichlorohydrin. This is done using non-aqueous alkali metal carbonate as a base to form the epoxy intermediate 1-(4-acetoxy-2,3,5-trimethylphenoxy)-2,3-epoxypropane. The inorganic salts are filtered off, the organic layer concentrated, and the residue recrystallised from an organic solvent. This epoxide is then treated with isopropylamine in solvent or neat, heated to reflux and dried to give metipranolol.
Metipranolol has the molecular formula of C17H27NO4 and a molecular weight of 309.4 g/mol. It is a non-selective beta-adrenergic blocker which appears as a white, odourless crystalline powder in solid form. It has a melting point of around 106 degree Celsius and moderate water solubility of around 589 mg/L at physiological pH. It features a substituted 1-(isopropylamino)-3-(4-morpholinophenoxy)propan-2-ol structure with a phenyl acetate moiety, one chiral centre contributing to stereospecific beta-blockade activity. It has a logP value of 2.66, indicating moderate lipophilicity suitable for ocular penetration, and a pKa of 9.54, reflecting its weakly basic nature due to the amine group.